Vivoryon Therapeutics is preparing a phase IIa / IIb study on PQ912. The company is supported by the University of California. The study is scheduled to start in 2021. The study is to end in 2023. The study is to include 180 people. The US study will complement a study in Europe that is scheduled to start in the second half of 2020.
FMR analysts believe the study will cost around 25 million euros. You also receive an NIH grant. It is likely that 8.8 million euros will flow into the study.
As before, the analysts issue a buy recommendation for Vivoryon’s shares. The target price remains at 9.00 euros.
For the current year, the analysts expect a loss of 6.0 million euros, which should rise to 18.4 million euros in 2021. In 2022, the minus should be 18.4 million euros.
Vivoryon’s shares today lost 2.9 percent to EUR 3,875.
Some investors may say Vivoryon something under the old name. The company operated as a probiodrug until a year ago.